Ascendis Pharma A (ASND) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$19429.5.
- Ascendis Pharma A's EPS (Weighted Average and Diluted) fell 21614.85% to -$19429.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$19429.5, marking a year-over-year decrease of 21614.85%. This contributed to the annual value of -$7.07 for FY2024, which is 9047.71% up from last year.
- Ascendis Pharma A's EPS (Weighted Average and Diluted) amounted to -$19429.5 in Q3 2025, which was down 21614.85% from $18132.4 recorded in Q2 2025.
- Ascendis Pharma A's 5-year EPS (Weighted Average and Diluted) high stood at $56971.7 for Q1 2024, and its period low was -$59937.3 during Q1 2025.
- For the 5-year period, Ascendis Pharma A's EPS (Weighted Average and Diluted) averaged around -$1981.3, with its median value being -$14.26 (2021).
- In the last 5 years, Ascendis Pharma A's EPS (Weighted Average and Diluted) crashed by 23261.31% in 2023 and then skyrocketed by 20098.75% in 2024.
- Ascendis Pharma A's EPS (Weighted Average and Diluted) (Quarter) stood at -$14.97 in 2021, then tumbled by 101.86% to -$30.22 in 2022, then soared by 55.17% to -$13.55 in 2023, then surged by 123584.79% to $16728.2 in 2024, then crashed by 216.15% to -$19429.5 in 2025.
- Its EPS (Weighted Average and Diluted) was -$19429.5 in Q3 2025, compared to $18132.4 in Q2 2025 and -$59937.3 in Q1 2025.